# PERSIAN (NCT05717660)

> APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05717660
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Azienda Ospedaliero-Universitaria Careggi
- Conditions: Oligometastatic Hormone Sensitive Prostate Cancer
- Interventions: SBRT on all sites of metastatic disease+Apalutamide
- Enrollment: 180
- Primary outcome: Complete biochemical response

## HCP commentary on PERSIAN so far

What clinicians have said in podcasts, YouTube videos and X posts we have indexed. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=persian-nct05717660